Left Atrial Isolation and Appendage Occlusion in Patients With Atrial Fibrillation at End-Stage Left Atrial Fibrotic Disease

Impact of pre-existing left atrial appendage occluder on catheter ablation of atrial fibrillation

BACKGROUND

Patients with drug-refractory atrial fibrillation (AF) and pre-existing left atrial appendage occluder (LAAO) device may need pulmonary vein isolation (PVI). In this pioneer study, we investigated the impact of pre-existing LAAO on AF substrates and outcomes of PVI.

METHODS

From our AF registry, 65 drug-refractory patients with LAAO (72.1±11.4 years old; CHA₂DS₂-VASc score 3.7±2.1) were included for PVI. A balanced control group with 124 patients without LAAO receiving PVI (70.9±10.2 years old, CHA₂DS₂-VASc 3.6±1.9) were included for comparison.

RESULTS

We found PVI is feasible in patients with AF with pre-existing LAAO without new peridevice leak. Two patients with LAAO and one without LAAO had stroke during the procedure (2/65 vs 1/124, p=0.272). Complete isolation of left-sided PVs might not be achieved if the device covered the ridge joining the left atrial (LA) appendage to the body of LA. Local electrogram could be detected over LAAO and there was propagation of conduction over the occluder either under sinus rhythm or under atrial arrhythmia. LAAO might modulate LA substrate and induce peridevice fibrosis, peridevice LA flutter and complex fractionate atrial electrogram. The AF recurrent rate at 1 year was similar between the two groups (9.2% vs 8.8%).

CONCLUSIONS

This pioneer study first showed impacts of LAAO on LA substrate and PVI procedure.

Low-Voltage Myocardium-Guided Ablation Trial of Persistent Atrial Fibrillation

BACKGROUND: Clinically effective ablation approaches for patients with persistent atrial fibrillation (AF) are still being debated. So far, ablation targets and strategies beyond pulmonary vein isolation (PVI) have failed to show systematic outcome improvement in randomized controlled clinical trials. METHODS: We conducted a multicenter, randomized trial to determine whether PVI plus individualized substrate ablation of atrial low-voltage myocardium improves outcome in patients with persistent AF. We randomly assigned 324 patients in a 1:1 ratio to receive PVI alone (163 patients; PVI only) or PVI plus substrate modification (161 patients; PVI+SM). The primary study end point was the first recurrence of an atrial arrhythmia longer than 30 seconds after single ablation, with 3 months blanking, using serial 7-day electrocardiogram recordings over 12 months of observation. Patients were also encouraged to receive implantable cardiac monitors. RESULTS: The primary study end point occurred in 75 PVI-only patients (50%) and in 54 PVI+SM patients (35%) (Kaplan–Meier event rate estimates: hazard ratio=0.62, 95% confidence interval [CI]=0.43 to 0.88, log rank P=0.006). Adverse events occurred in three PVI-only patients (1.8%) and in six PVI+SM patients (3.7%) (difference: −1.9 percentage points, 95% CI=−5.5 to 1.7 percentage points). Implant monitoring was used in 242 patients. Among them, 65 PVI-only patients (55%) versus 47 PVI+SM patients (39%) experienced recurrences (difference: 15 percentage points, 95% CI=3 to 28 percentage points). CONCLUSIONS: In this randomized trial, PVI plus individualized ablation of atrial low-voltage myocardium significantly improved outcomes in patients with persistent AF. (ClinicalTrials.gov number, NCT02732626.)

Persistent Atrial Fibrillation in Elderly Patients: Limited Efficacy of Pulmonary Vein Isolation

(1) Background: Cryoballoon pulmonary vein isolation (cryoPVI) is established for symptomatic paroxysmal atrial fibrillation (AF) treatment, but its value in persistent AF is less clear. In particular, limited data are available on its efficacy in elderly patients (≥75 years) with persistent AF. Age is an important modifier of AF progression and represents a risk-factor for AF recurrence. (2) Methods: Prospective, single-center observational study to evaluate the impact of age on efficacy and safety of cryoPVI in elderly patients. Primary efficacy endpoint was symptomatic AF recurrence after 90-day blanking period. Primary safety endpoints were death from any cause, procedure-associated complications or stroke/transient ischemic attack. Median follow-up was 17 months (range 3−24). (3) Results: We included 268 patients with persistent AF (94 ≥ 75 years of age). Multivariate Cox regression analysis identified age as the only independent factor influencing AF recurrence in the overall cohort (p = 0.006). To minimize confounding bias in efficacy and safety analysis of cryoPVI, we matched younger and elderly patients with respect to baseline characteristics. At 24 months, primary efficacy endpoint occurred in 13/69 patients <75 years and 31/69 patients ≥75 years of age (24 months Kaplan−Meier event-rate estimates, HR 0.34; 95% CI, 0.19 to 0.62; log-rank p = 0.0004). No differences were observed in the occurrence of safety end points. (4) Conclusions: Elderly (≥75 years) patients with persistent AF undergoing cryoPVI had an approximately threefold higher risk of symptomatic AF recurrence than matched younger patients. Accordingly, other treatment modalities may be evaluated in this population.

Electro-characteristics of Myocardial Pouches and Reduction of the Frequency of Steam Pops During Radiofrequency Ablation

Background: Radiofrequency ablation (RFA) effectively treats arrhythmia. Steam pop (SP) is a dangerous complication of RFA, which can lead to pericardial tamponade or even death.

Objective: This study aimed to explore the electro-characteristics of myocardial pouches, and the relationship between SP, pouch, and impedance.

Methods: Swine myocardium was divided into the pouch group and smooth myocardium group. Continuous RFA at 50 W was applied. The initial impedance reduction within the first 3 s of ablation and the time from the start of ablation to SP were recorded. After enabling the delta impedance cutoff function, RFA was performed at different percentage of delta impedance (PDI) cutoff thresholds.

Results: The impedance was higher for the pouch myocardium compared to the smooth myocardium (123.22 ± 8.63 Ω and 95.75 ± 4.75 Ω, respectively; p < 0.001). The RFA duration before SPs was shorter in the pouch group compared to the smooth myocardium group [9 s (interquartile range, IQR: 6.25–13 s) and 33 s (IQR: 26.25–40.75 s), respectively; p < 0.001]. Within the first 3 s of RFA, impedance reduction (24.65 ± 6.57 Ω and 12.78 ± 3.35 Ω, respectively; p < 0.001) and PDI [19.18% (IQR: 16.39–24.20%) and 12.96% (IQR: 11.17–14.39%), respectively; p < 0.001] were greater in the pouch group compared to the smooth myocardium group. A PDI of 15% and delta time of 3 s effectively reduced the frequency of SPs without seriously affecting RFA use.

Conclusion: SPs occur more frequently in the pouch area during RFA. Appropriate delta impedance cutoff settings (PDI: 15%; delta time: 3 s) can reduce the frequency of SPs and improve the RFA safety.